Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Prevention of Venous Thromboembolism: Elective hip replacement surgery Age: Adult |
Dose: Tablet – 2.5 mg Frequency: twice daily Duration: 32-38 days Note: The initial dose should be taken 12-24 hours post-operation. |
|
Indication: Prevention of Venous Thromboembolism: Elective knee replacement surgery Age: Adult |
Dose: Tablet – 2.5 mg Frequency: twice daily Duration: 10-14 days Note: The initial dose should be taken 12-24 hours post-operation. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Treatment of venous thromboembolism and reduction in risk of recurrent venous thromboembolism Age: Birth and older |
Dose: By mouth – 0.3 mg Frequency: twice daily Duration: Days 1-7 Note: by mouth (oral) |
|
Indication: Treatment of venous thromboembolism and reduction in risk of recurrent venous thromboembolism Age: Birth and older |
Dose: By mouth – 0.15 mg Frequency: twice daily Duration: Days 8+ Note: by mouth (oral) |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Deep Vein Thrombosis Condition: Renal impairment, including end-stage renal disease on dialysis |
Dose: Dosage Form with Dose: Not specified – Not specified Note: No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with end-stage renal disease on dialysis or patients with a creatinine clearance less than 15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-factor Xa activity) data in study subjects with end-stage renal disease maintained on dialysis |
|
Indication: Nonvalvular atrial fibrillation Condition: Mild-to-moderate renal impairment |
Dose: Dosage Form with Dose: Not specified – Not specified Note: No dosage adjustment required |
Administration
- Can be taken with or without food
- Take at regular intervals
Side Effect
- Epistaxis
- haematoma
- anaemia
- haematuria
- contusion
- nausea
- GI
- rectal or gingival haemorrhage
- Epidural or spinal haematoma
- fatal bleeding
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Strong dual CYP3A4 and P-glycoprotein (P-gp) inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, ritonavir)
|
Increased exposure
|
|
Drugs affecting haemostasis (e.g. aspirin, heparin, fibrinolytics, SSRIs, NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac), serotonin norepinephrine reuptake inhibitors)
|
Increased risk of bleeding
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Active Bleeding
|
Risk of severe hemorrhage
|
|
Hepatic Disease with Coagulopathy
|
Risk of bleeding complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.